1-20 of 136
Nizar J. Bahlis, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Peripheral Neuropathy Symptoms, Pain and Functioning in Relapsed or Refractory Multiple Myeloma Patients Treated with Selinexor, Bortezomib, and Dexamethasone

Larysa Sanchez, MD, Xavier Leleu, MD, Jennifer Beaumont, Hailin Yu, Stacie Hudgens, MA, Holger W Auner, MD PhD, Hang Quach, MD, Sosana Delimpasi, MD, Ivan Spicka, MD PhD, Luděk Pour, MD, Meletios A Dimopoulos, Halyna Pylypenko, MD, Vadim A Doronin, MD, Ganna Usenko, MD, Roman Hajek, MD PhD, Reuben Benjamin, MD, Christopher P. Venner, MD, Mamta Garg, MD FRCP, FRCPath, Don A. Stevens, MD, Sundar Jagannath, MD, Philippe Moreau, MD, Moshe Levy, MD, Nizar J. Bahlis, MD, Thierry Facon, MD, Yi Chai, Xiwen Ma, Shijie Tang, Hoyee Leong, Jatin J. Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Paul G. Richardson, MD, Sebastian Grosicki, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–41.
https://doi.org/10.1182/blood-2020-141319
Published: 2020
Journal Articles

Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Alexander M. Lesokhin, MD, Moshe Y. Levy, MD, Andrew P. Dalovisio, MD, Nizar J. Bahlis, MD, Melhem Solh, MD, Michael Sebag, MD PhD FRCPC, Andrzej Jakubowiak, MD PhD, Yogesh S. Jethava, MBBS, MD FRCPath, MRCP, Caitlin L. Costello, MD, Michael P. Chu, MD, Michael R. Savona, MD, Cristina Gasparetto, MD, Suzanne Trudel, MD MSC, FRCPC, Jeffrey Chou, MD PhD, Chandrasekhar Udata, PhD, Cynthia Basu, PhD, Heike I. Krupka, PhD PMP, Noopur S. Raje, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 8–9.
https://doi.org/10.1182/blood-2020-133355
Published: 2020
Journal Articles

Once Weekly Selinexor, Bortezomib, and Dexamethasone Versus Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses from the Phase 3 Boston Study

Holger W Auner, MD PhD, Maria Gavriatopoulou, Sosana Delimpasi, MD, Maryana Simonova, MD, Ivan Spicka, MD PhD, Ludek Pour, MD, Meletios A Dimopoulos, Irina Kryachok, Professor, Halyna Pylypenko, MD, Xavier Leleu, MD, Vadim A Doronin, MD, Ganna Usenko, MD, Roman Hajek, MD, Reuben Benjamin, FRCPath, MRCP, MBBS, PhD, Tuphan Kanti Dolai, MBBS, MD DNB, DM, Dinesh Kumar Sinha, MD, Christopher P. Venner, MD, Mamta Garg, MD FRCP, FRCPath, Don A. Stevens, MD, Hang Quach, MDFRACP,FRCPA,MBBS, Sundar Jagannath, MD, Philippe Moreau, MD, Moshe Y. Levy, MD, Ashraf Z. Badros, MD, Larry D. Anderson, Jr., MD PhD, Nizar J. Bahlis, MD, Thierry Facon, MD, Maria Mateos, MD PhD, Michele Cavo, Anita A. Joshi, Yi Chai, Melina Arazy, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Paul G. Richardson, MD, Sebastian Grosicki, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–18.
https://doi.org/10.1182/blood-2020-137303
Published: 2020
Journal Articles

Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study

Maria Mateos, MD PhD, Sundar Jagannath, MD, Sosana Delimpasi, MD, Maryana Simonova, MD, Ivan Spicka, MD PhD, Ludek Pour, MD, Irina Kryachok, MD, Maria Gavriatopoulou, Meletios A Dimopoulos, Halyna Pylypenko, MD, Holger W Auner, MD PhD, Xavier Leleu, MD, Vadim A Doronin, MD, Ganna Usenko, MD, Reuben Benjamin, MD, Tuphan Kanti Dolai, MBBS, MD DNB, DM, Dinesh Kumar Sinha, MD, Christopher P. Venner, MD, Mamta Garg, MD FRCP, FRCPath, Don A. Stevens, MD, Hang Quach, MDFRACP,FRCPA,MBBS, Philippe Moreau, MD, Moshe Y. Levy, MD, Ashraf Z. Badros, MD, Larry D. Anderson, Jr., MD PhD, Nizar J. Bahlis, MD, Thierry Facon, MD, Michele Cavo, Yi Chai, Melina Arazy, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Paul G. Richardson, MD, Sebastian Grosicki, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 50–52.
https://doi.org/10.1182/blood-2020-137574
Published: 2020
Journal Articles

Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

David S. Siegel, MD PhD, Gary J. Schiller, MD, Christy J. Samaras, DO, Michael Sebag, MD PhD FRCPC, Jesus G. Berdeja, MD, Siddhartha Ganguly, MD, Jeffrey V. Matous, MD, Kevin W Song, MD FRCPC, Christopher S. Seet, MD PhD, Mirelis Acosta-Rivera, Michael Bar, Donald P. Quick, MD, Bertrand M. Anz, III, MD, Gustavo A. Fonseca, MD, Donna E. Reece, MD, Kim Lee, Weiyuan Chung, Amit Agarwal, MD PhD, Nizar J. Bahlis, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–17.
https://doi.org/10.1182/blood-2020-134189
Published: 2020
Journal Articles

Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study

Shaji K. Kumar, MD, Thierry Facon, MD, Saad Z. Usmani, MDMBBS,MBA, Torben Plesner, MD DSc, Robert Z. Orlowski, MDPhD, Cyrille Touzeau, Supratik Basu, Nizar J. Bahlis, MD, Hartmut Goldschmidt, MD, Michael E. O'Dwyer, MD, Christopher P. Venner, MD, Katja Weisel, MD, Cyrille Hulin, MD, Lionel Karlin, MD, Meir Preis, MD PhD, Annemiek Broyl, MD PhD, William Renwick, Markus Hansson, MD, Maria Krevvata, PhD, Jianping Wang, Rian Van Rampelbergh, Jon Ukropec, PhD, Clarissa M. Uhlar, Rachel Kobos, MD, Aurore Perrot
Journal: Blood
Blood (2020) 136 (Supplement 1): 24–26.
https://doi.org/10.1182/blood-2020-134847
Published: 2020
Journal Articles

Sustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant-Ineligible (TIE) Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Treated with Daratumumab-Based Regimens: Analysis of Maia and Alcyone

Jesus F. San-Miguel, MD PhD, Herve Avet-Loiseau, Bruno Paiva, PhD, Shaji K. Kumar, MD, Meletios A. Dimopoulos, MD, Thierry Facon, MD, Maria-Victoria Mateos, MD PhD, Cyrille Touzeau, Andrzej Jakubowiak, MD PhD, Saad Z. Usmani, MDMBBS,MBA, Gordon Cook, MD, Michele Cavo, Hang Quach, MDFRACP,FRCPA,MBBS, Jon Ukropec, PhD, Priya Ramaswami, Huiling Pei, PhD, Steven Sun, Jianping Wang, Maria Krevvata, PhD, Nikki DeAngelis, Christoph Heuck, Rian Van Rampelbergh, Anupa Kudva, MD, Rachel Kobos, MD, Ming Qi, MD PhD, Nizar J. Bahlis, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–20.
https://doi.org/10.1182/blood-2020-134928
Published: 2020
Journal Articles

Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel Celmod Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma

Lilly Wong, Manisha Lamba, María Dolores Jiménez Nuñez, Daniel Bauer, Paul G. Richardson, MD, Nizar J. Bahlis, MD, Annette J. Vangsted, Karthik Ramasamy, Suzanne Trudel, Joaquín Martínez-Lopez, María-Victoria Mateos, Paula Rodriguez-Otero, MD PhD, Sagar Lonial, MD FACP, Rakesh Popat, Albert Oriol, Chatchada Karanes, Robert Z. Orlowski, MDPhD, Jesus G. Berdeja, MD, Michael Pourdehnad, Daniel W. Pierce
Journal: Blood
Blood (2020) 136 (Supplement 1): 47–48.
https://doi.org/10.1182/blood-2020-137161
Published: 2020
Journal Articles

Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study

Maria Mateos, MD PhD, Maria Gavriatopoulou, Thierry Facon, MD, Holger W Auner, MD PhD, Xavier Leleu, MD, Roman Hajek, MD, Meletios A Dimopoulos, Sosana Delimpasi, MD, Maryana Simonova, MD, Ivan Spicka, MD PhD, Ludek Pour, MD, Irina Kryachok, MD, Halyna Pylypenko, MD, Vadim A Doronin, MD, Ganna Usenko, MD, Reuben Benjamin, FRCPath, MRCP, MBBS, PhD, Tuphan Kanti Dolai, MBBS, MD DNB, DM, Dinesh Kumar Sinha, MD, Christopher P. Venner, MD, Mamta Garg, MD FRCP, FRCPath, Don A. Stevens, MD, Hang Quach, MD, Sundar Jagannath, MD, Philippe Moreau, MD, Moshe Levy, MD, Ashraf Z. Badros, MD, Larry D. Anderson, Jr., MD PhD, Nizar J. Bahlis, MD, Michele Cavo, Yi Chai, Melina Arazy, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Paul G. Richardson, MD, Sebastian Grosicki, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 48–50.
https://doi.org/10.1182/blood-2020-138391
Published: 2020
Journal Articles

Cite-Seq Profiling of T Cells in Multiple Myeloma Patients Undergoing BCMA Targeting CAR-T or Bites Immunotherapy

Noemie Leblay, PhD, Ranjan Maity, PhD, Elie Barakat, Sylvia McCulloch, MD MSc, Peter Duggan, MD FRCPC, Victor Jimenez-Zepeda, MD, Nizar J. Bahlis, MD, Paola Neri, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–12.
https://doi.org/10.1182/blood-2020-137650
Published: 2020
Journal Articles

Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)

Christine I Chen, MD, Nizar J. Bahlis, MD, Cristina Gasparetto, MD, Sascha A Tuchman, MD, Brea Lipe, MD, Muhamed Baljevic, MD, Rami Kotb, MD, Heather J Sutherland, MD PhD, William I Bensinger, MD, Michael Sebag, MD PhD FRCPC, Richard LeBlanc, MD FRCPC, Christopher P. Venner, MD, Gary J. Schiller, MD, Suzanne Lentzsch, MD PhD, Natalie S. Callander, MD, Adriana C Rossi, MD MSc, Heidi Sheehan, Dane Van Domelen, PhD, Kai Kazuharu, MD PhD, Hongwei Wang, MD PhD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Darrell J White, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-139858
Published: 2020
Journal Articles

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

Michael Sebag, MD PhD FRCPC, Nizar J. Bahlis, MD, Christopher P. Venner, MD, Arleigh McCurdy, MD BSc, C. Tom Kouroukis, MDMSc,FRCPC, Jesse Shustik, MD, Rami Kotb, MD, Darrell J White, MD, Julie Stakiw, MD, Nicole B. Laferriere, MD PhD, Anthony Reiman, MD, Fernando Camacho, PhD, Molei Fu, Engin Gul, BSc, Donna E. Reece, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 6.
https://doi.org/10.1182/blood-2020-141087
Published: 2020
Journal Articles

Selinexor, Lenalidomide and Dexamethasone (SRd) for Patients with Relapsed/Refractory and Newly Diagnosed Multiple Myeloma

Darrell J White, MD, Richard LeBlanc, MD FRCPC, Muhamed Baljevic, MD, Nizar J. Bahlis, MD, Suzanne Lentzsch, MD PhD, Christopher P. Venner, MD, Cristina Gasparetto, MD, Christine I Chen, MD, Brea Lipe, MD, Sascha A Tuchman, MD, Heather J Sutherland, MD PhD, Rami Kotb, MD, Michael Sebag, MD PhD FRCPC, Natalie S. Callander, MD, William I Bensinger, MD, Adriana C Rossi, MD MSc, Heidi Sheehan, Dane Van Domelen, PhD, Tianjun Zhou, MD PhD, Kai Kazuharu, MD PhD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Gary J. Schiller, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-140141
Published: 2020
Journal Articles

Selinexor in Combination with Carfilzomib and Dexamethasone, All Once Weekly (SKd), for Patients with Relapsed/Refractory Multiple Myeloma

Cristina Gasparetto, MD, Brea Lipe, MD, Sascha A Tuchman, MD, Natalie S. Callander, MD, Suzanne Lentzsch, MD PhD, Muhamed Baljevic, MD, Adriana C Rossi, MD MSc, Nizar J. Bahlis, MD, Darrell J White, MD, Christine I Chen, MD, Heather J Sutherland, MD PhD, Rami Kotb, MD, Richard LeBlanc, MD FRCPC, Michael Sebag, MD PhD FRCPC, Christopher P. Venner, MD, William I Bensinger, MD, Heidi Sheehan, Dane Van Domelen, PhD, Kai Kazuharu, MD PhD, Gary J. Schiller, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 14–15.
https://doi.org/10.1182/blood-2020-137183
Published: 2020
Journal Articles

Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study

Shambavi Richard, MD, Ajai Chari, MD, Sosana Delimpasi, MD, Maryana Simonova, MD, Ivan Spicka, MD PhD, Ludek Pour, MD, Irina Kryachok, MD, Meletios A Dimopoulos, Halyna Pylypenko, MD, Holger W Auner, MD PhD, Xavier Leleu, MD, Vadim A Doronin, MD, Ganna Usenko, MD, Roman Hajek, MD, Reuben Benjamin, FRCPath, MRCP, MBBS, PhD, Tuphan Kanti Dolai, MBBS, MD DNB, DM, Dinesh Kumar Sinha, MD, Christopher P. Venner, MD, Mamta Garg, MD FRCP, FRCPath, Don A. Stevens, MD, Hang Quach, MDFRACP,FRCPA,MBBS, Sundar Jagannath, MD, Philippe Moreau, MD, Moshe Y. Levy, MD, Ashraf Z. Badros, MD, Larry D. Anderson, Jr., MD PhD, Nizar J. Bahlis, MD, Thierry Facon, MD, Maria-Victoria Mateos, MD PhD, Michele Cavo, Hua Chang, PhD, Yosef Landesman, PhD, Anita A. Joshi, Yi Chai, Melina Arazy, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Sebastian Grosicki, MD PhD, Paul G. Richardson, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35–36.
https://doi.org/10.1182/blood-2020-137154
Published: 2020
Journal Articles

A Phase 1b Study to Assess the Combination of Selinexor and Daratumumab in Patients with Relapsed / Refractory Multiple Myeloma Previously Exposed to Proteasome Inhibitors (PI) and Immunomodulatory Drugs (IMiDs)

Cristina J. Gasparetto, MD, Suzanne Lentzsch, MD PhD, Gary J Schiller, MD, William Bensinger, MD, Nizar J. Bahlis, MD, Heather J. Sutherland, MD PhD FRCPC, Darrell J White, MD, Michael Sebag, MD PhD, Rami Kotb, MD, Christopher P. Venner, MD, Richard LeBlanc, MDFRCPC, Christine I Chen, MD FRCP(C), Aldo Del Col, BSPharm, MBA, Michael G. Kauffman, MD PhD, Sharon Shacham, PhD MBA, Jacqueline Jeha, Jean-Richard Saint-Martin, Jatin Shah, MD, Brea C. Lipe, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3100.
https://doi.org/10.1182/blood.V130.Suppl_1.3100.3100
Published: 2017
Journal Articles

Safety and Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed and Refractory Multiple Myeloma: Final Results from GEN501 and Sirius

Saad Z Usmani, MD, Hareth Nahi, Brendan M Weiss, MD, Nizar J. Bahlis, MD, Andrew Belch, Henk M Lokhorst, Peter M. Voorhees, MD, Paul G Richardson, MD, Clarissa Uhlar, Jianping Wang, Ming Qi, Sagar Lonial, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3107.
https://doi.org/10.1182/blood.V130.Suppl_1.3107.3107
Published: 2017
Journal Articles

Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer (NK) Cells with a Distinct Phenotype and Expansion of Effector Memory T-Cells in Pollux, a Phase 3 Randomized Study

Niels WCJ Van De Donk, Homer Adams, III, Greet Vanhoof, Jakub Krejcik, MD, Koen Van der Borght, Tineke Casneuf, PhD, Tina Smets, Amy Axel, Yann Abraham, Hugo Ceulmans, Frederik Stevenaert, Saad Z Usmani, MD, Torben Plesner, MD, Sagar Lonial, MD, Berris van Kessel-Welmers, Henk M Lokhorst, Tuna Mutis, PhD, Nizar J. Bahlis, MD, Jordan Schecter, Christopher Chiu, Hervé Avet-Loiseau, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3124.
https://doi.org/10.1182/blood.V130.Suppl_1.3124.3124
Published: 2017
Journal Articles

Targeted-Capture Sequencing Approach to V(D)J Rearrangement, Immunoglobulin (Ig) Translocation and Mutation Detection in Multiple Myeloma (MM): Potential Applications in Minimal Residual Disease (MRD) Analysis and Comparison to Multiparameter Flow Cytometry (MFC) in the Myeloma Canada Research Network (MCRN) 001 Study with Intravenous Busulfan and Melphalan (BuMel) Conditioning Followed By Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM)

Signy Chow, MD FRCP(C), Donna Reece, MD FRCP(C), Jonathan J. Keats, PhD, P. Leif Bergsagel, MD, Nizar J. Bahlis, MD, Paola Neri, MD, Giovanni Piza Rodriguez, MD, Michael Sebag, MD PhD, Darrell J White, MD, Kevin Song, MD FRCP(C), Terrance Comeau, MD, Christopher P. Venner, MD, Christine I Chen, MD FRCP(C), Jean Roy, MD, Martha L Louzada, MD, Julie Stakiw, MD FRCP(C), Andrea Kew, MDFRCP(C), Vishal Kukreti, MD FRCP(C), Anca Prica, MD FRCP(C), Rodger Tiedemann, MBChB, PhD, Mariela Aura Pantoja, PhD MSc, Harminder Kaur Paul, MSc, Trevor J. Pugh, PhD, Suzanne Trudel, MD FRCP(C)
Journal: Blood
Blood (2017) 130 (Supplement 1): 3057.
https://doi.org/10.1182/blood.V130.Suppl_1.3057.3057
Published: 2017
Journal Articles

Selinexor in Combination with Weekly Low Dose Bortezomib and Dexamethasone (SVd) Induces a High Response Rate with Durable Responses in Patients with Refractory Multiple Myeloma (MM)

Nizar J. Bahlis, MD, Heather Sutherland, MD, Darrell J White, MD, Michael Sebag, MD PhD, Suzanne Lentzsch, MD PhD, Rami Kotb, MD, Christopher P. Venner, MD, Cristina J. Gasparetto, MD, Gary J Schiller, MD, Richard LeBlanc, MDFRCPC, William Bensinger, MD, Brea Lipe, MD, Aldo Del Col, BSPharm, MBA, Michael G. Kauffman, MD PhD, Sharon Shacham, PhD MBA, Jacqueline Jeha, Jean-Richard Saint-Martin, BS, Jatin Shah, MD, Christine I Chen, MD FRCP(C)
Journal: Blood
Blood (2017) 130 (Supplement 1): 3135.
https://doi.org/10.1182/blood.V130.Suppl_1.3135.3135
Published: 2017